NCT06557421View on ClinicalTrials.gov

De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 12, 2025

Primary Completion Date

November 1, 2028

Study Completion Date

November 1, 2028

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Venetoclax

complete discontinuation of Venetoclax

DRUG

Azacitidine

complete discontinuation of Azacitidine

Trial Locations (1)

13273

RECRUITING

Institut Paoli-Calmettes, Marseille

All Listed Sponsors
lead

Institut Paoli-Calmettes

OTHER

NCT06557421 - De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients | Biotech Hunter | Biotech Hunter